Trial ID	Intervention(s) and comparator(s)	Participants included in analysis (N)	Participants discontinuing trial due to an adverse event (N)	Participants discontinuing trial due to an adverse event (%)	Participants with at least 1 hospitalisation (N)	Participants with at least 1 hospitalisation (%)	Participants with at least 1 outpatient treatment (N)	Participants with at least 1 outpatient treatment (%)
Ensor 2015	I: sucralose	207	‐	‐	‐	‐	‐	‐
	C: D‐tagatose	185	‐	‐	‐	‐	‐	‐
Barriocanal 2008	I: steviol glycoside	23	0	0	‐	‐	‐	‐
	C: placebo	23	0	0	‐	‐	‐	‐
Maki 2008	I: rebaudioside A	60	2	3.3	‐	‐	‐	‐
	C: placebo	62	1	1.6	‐	‐	‐	‐
Grotz 2003	I: sucralose	67	0	0	‐	‐	‐	‐
	C: placebo	69	0	0	‐	‐	‐	‐
Colagiuri 1989	I: aspartame	‐	‐	‐	‐	‐	‐	‐
	C: sucrose	‐	‐	‐	‐	‐	‐	‐
Cooper 1988	I: saccharin and starch	‐	‐	‐	‐	‐	‐	‐
	C: sucrose	‐	‐	‐	‐	‐	‐	‐
Chantelau 1985	I: sodium‐cyclamate	‐	‐	‐	‐	‐	‐	‐
	C: sucrose	‐	‐	‐	‐	‐	‐	‐
Nehrling 1985	I: aspartame	30	1	3.3	‐	‐	‐	‐
	C: placebo (cornstarch)	33	0	0	‐	‐	‐	‐
Stern 1976	I: aspartame	36	1	2.8	‐	‐	‐	‐
	C: placebo	33	0	0	‐	‐	‐	‐
‐: denotes not reported C: comparator; I: intervention; N: number of participants.